- Home
- MUFG vs NVO Comparison
MUFG vs NVO Comparison
Compare MUFG & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | NVO |
|---|---|---|
| Founded | 1880 | 1923 |
| Country | Japan | Denmark |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.9B | 212.7B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | MUFG | NVO |
|---|---|---|
| Price | $18.87 | $62.02 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $54.25 |
| AVG Volume (30 Days) | 2.7M | ★ 20.8M |
| Earning Date | 02-03-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.14% | 1.97% |
| EPS Growth | N/A | ★ 10.06 |
| EPS | 0.76 | ★ 3.67 |
| Revenue | $38,565,096,137.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $2.23 | $7.25 |
| Revenue Next Year | $7.31 | $0.24 |
| P/E Ratio | $24.38 | ★ $16.45 |
| Revenue Growth | N/A | ★ 16.64 |
| 52 Week Low | $10.46 | $43.08 |
| 52 Week High | $18.90 | $93.80 |
Technical Indicators
Market Signals| Indicator | MUFG | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 85.16 | 72.64 |
| Support Level | $15.75 | $56.29 |
| Resistance Level | $15.97 | $60.63 |
| Average True Range (ATR) | 0.21 | 1.44 |
| MACD | 0.27 | 0.59 |
| Stochastic Oscillator | 99.21 | 96.28 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.